We are pleased to present the Haigh & Company 2023 BiotechEquity Report.
The purpose of our analysis is to provide our clients, colleagues and the broader life sciences community an up-to-date look at equity usage through the third quarter of 2023 and to provide a resource for your year-end and new year planning process.
Some Key Results: